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Does Lung Adenocarcinoma Subtype Predict Patient
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A Clinicopathologic Study Based on the New International
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European Respiratory Society International Multidisciplinary Lung
Adenocarcinoma Classification
Prudence A. Russell, MBBS, FRCPA,* Zoe Wainer, BMBS,†‡ Gavin M. Wright, MBBS, FRACS,†‡§
Marissa Daniels, MBBS,§ Matthew Conron, MBBS, FRACP,
and Richard A. Williams, MBBS, FRCPA, PhD*
Introduction: Lung adenocarcinoma is a heterogeneous group of
tumors with a highly variable prognosis, not well predicted by the
current pathologic classification system. The 2004 World Health
Organization classification results in virtually all tumors encoun-
tered in clinical practice being allocated to the adenocarcinoma of
mixed subtype category. A new classification developed by an
international multidisciplinary expert panel sponsored by the Inter-
national Association for the Study of Lung Cancer, American
Thoracic Society, and European Respiratory Society, is based on
histomorphologic subtype and has recently been validated in a North
American series of 514 stage I lung adenocarcinomas. We investi-
gated the relationship between the new classification and patient
survival in a series of Australian patients with stages I, II, and III
lung adenocarcinoma.
Methods: We identified 210 patients from a surgical database who
underwent resection of lung adenocarcinoma from 1996 to 2009.
Two pathologists, blinded to patient outcome, independently per-
formed histopathologic subtyping according to the new classifica-
tion. Kaplan-Meier curves were used to calculate 5-year survival for
each separate histopathologic subtype/variant. Univariate and mul-
tivariate analyses were undertaken to control for validated prognos-
tic factors.
Results: We confirmed that the new subtypes of adenocarcinoma in
situ, minimally invasive adenocarcinoma and lepidic-predominant
adenocarcinoma had a 5-year survival approaching 100%, whereas
micropapillary-predominant and solid with mucin-predominant adeno-
carcinomas were associated with particularly poor survival. Papillary-
predominant and acinar-predominant adenocarcinomas had an interme-
diate prognosis. This effect persisted after controlling for stage.
Conclusions: Classification of lung adenocarcinoma according to
the new International Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society classifi-
cation correlated with 5-year survival. These relationships persisted
after controlling for known prognostic patient and tumor character-
istics. The new classification has advantages not only for individual
patient care but also for better selection and stratification for clinical
trials and molecular studies.
Key Words: Acinar, Lepidic, Papillary, Micropapillary, Solid with
mucin, Mucinous.
(J Thorac Oncol. 2011;6: 1496–1504)
Adenocarcinoma is the most common histopathologic typeof primary lung cancer1 and is a major focus of research
to improve patient survival. Similar to other solid organ
tumors, there is a wide spectrum of tumor behavior that is
poorly predicted by recognized prognostic factors such as
tumor node metastasis (TNM) stage at diagnosis. Although
the utilization of molecular profiles to guide patient manage-
ment strategies holds great promise, currently these tools are
expensive and, in many settings, unavailable. Different his-
tomorphologic patterns observed in adenocarcinoma subtypes
may provide additional prognostic information, on the as-
sumption that they are functional phenotypes reflecting an
underlying genotype. The use of histopathologic features to
predict tumor behavior is particularly attractive because it can
be obtained quickly and cheaply at the time of diagnosis.
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The 1999 World Health Organization (WHO) classifi-
cation of lung tumors introduced the adenocarcinoma of
mixed subtype category,2 partly due to a change in definition
of bronchioloalveolar carcinoma (BAC).3 Mixed subtype ad-
enocarcinoma was retained in the 2004 WHO classification of
lung tumors.4 However, a major shortcoming of both 1999/
2004 WHO classifications is that mixed subtype adenocarci-
noma is the most common subtype, comprising 94% of all
adenocarcinomas in one series.5 Although pathologically ac-
curate, it is of limited clinical utility as most adenocarcino-
mas will fall into this subtype despite having widely varied
clinical outcomes.6,7 Since the publication of 1999/2004
WHO classifications, there have been many advances in the
practice and understanding of oncology, surgery, radiology,
and molecular biology of lung adenocarcinoma. Recent work
is now bringing lung cancer pathology into line with these
other advances. In addition, a disconnect still exists between
the strict pathologic definition of solitary BAC according to
1999/2004 WHO classifications and the clinical use of the
term.6,8–11 To address these issues, an international multidis-
ciplinary panel of lung cancer experts including medical
oncologists, respiratory physicians, pathologists, surgeons,
molecular biologists, and radiologists was formed in 2008
sponsored by the International Association for the Study of
Lung Cancer (IASLC), American Thoracic Society (ATS),
and European Respiratory Society (ERS). The result of this
collaboration is a new adenocarcinoma classification called
the new IASLC/ATS/ERS International Multidisciplinary
Lung Adenocarcinoma Classification, presented in 2009,12
published in 2011,13 and listed in Table 1.
Primary aims of the new classification include provi-
sion of consistent terms and diagnostic criteria for adenocar-
cinoma subtypes, particularly for BAC and mixed subtype
adenocarcinoma, and incorporation of significant practice
changing advances in the fields of pathology, molecular
biology, oncology, radiology, and surgery into a classification
that is still principally based on histopathologic examina-
tion.13 Some of the most important changes include making
the terms BAC and mixed subtype adenocarcinoma obsolete.
In the new classification, BAC is called adenocarcinoma in
situ (AIS) and describes small (3 cm) solitary lesions with
100% lepidic growth. A related entity, previously sometimes
referred to as minimally invasive BAC,8 was not included in
1999/2004 WHO classifications but is introduced in the new
classification and called minimally invasive adenocarcinoma
(MIA). MIA describes small (3 cm) solitary adenocarcino-
mas with predominant lepidic growth and 5 mm invasion.
If resected, both AIS and MIA are associated with 100% or
near 100% disease-free survival3,14,15 and are usually nonmu-
cinous, although rare examples are mucinous and called
mucinous AIS and mucinous MIA in the new classification.13
The new classification divided mixed subtype adeno-
carcinoma into five invasive subtypes on the basis of com-
prehensive histologic subtyping.5 Comprehensive histologic
subtyping is a recently introduced process in which each
histopathologic subtype present in a tumor is estimated in 5%
increments followed by identification and classification of
that tumor according to the predominant histologic subtype.
The five invasive subtypes include three present in previous
WHO classifications, acinar, papillary, and solid with mucin,
and two new subtypes, lepidic and micropapillary patterns.13
Lepidic-predominant adenocarcinoma (LPA) has predominant
lepidic growth with more than 5 mm of invasion and may show
tumor necrosis or invasion of lymphovascular spaces or visceral
pleura.13 Micropapillary adenocarcinoma was not included in
previous WHO classifications, although it was referred to in the
2004 WHO classification4 and is a pattern of great significance
because of its poor prognosis.16–18
Variant adenocarcinomas listed in the new classifica-
tion include invasive mucinous, colloid, enteric, and fetal
adenocarcinomas.13 Mucinous BAC has been renamed inva-
sive mucinous adenocarcinoma in recognition that these tu-
mors have components of lepidic growth with columnar or
goblet cells with abundant intracellular mucin admixed with
invasive adenocarcinoma patterns with stromal invasion. In
addition, invasive mucinous adenocarcinoma, when com-
pared with AIS,13 has different radiologic,19 immunohisto-
chemical,20 and molecular features21 as well as prognosis.20
Recently, Yoshizawa et al.22 validated the new adeno-
carcinoma classification with a North American data set
comprising 514 stage I lung adenocarcinomas. They demon-
strated a correlation between adenocarcinoma subtypes, ac-
cording to the new definitions, and survival, indicating a
valuable prognostic role for the new classification.
Against this backdrop, we investigated the clinical
utility of the new adenocarcinoma classification to determine
TABLE 1. The New IASLC/ATS/ERS International
Multidisciplinary Classification of Lung
Adenocarcinoma in Resection Specimens
Preinvasive lesions
Atypical adenomatous hyperplasia
Adenocarcinoma in situ (3 cm, formerly BAC)
Nonmucinous
Mucinous
Mixed mucinous/nonmucinous
Minimally invasive adenocarcinoma (3 cm lepidic predominant tumor
with 5 mm invasion)
Nonmucinous
Mucinous
Mixed mucinous/nonmucinous
Invasive adenocarcinoma
Lepidic predominant (formerly nonmucinous BAC pattern, with 5 mm
invasion)
Acinar predominant
Papillary predominant
Micropapillary predominant
Solid predominant with mucin production
Variants of invasive adenocarcinoma
Invasive mucinous adenocarcinoma (formerly mucinous BAC)
Colloid
Fetal (low and high grade)
Enteric
Reprinted with permission from J Thorac Oncol 2011;6:244–285.
IASLC, International Association for the Study of Lung Cancer; ATS, American
Thoracic Society; ERS, European Respiratory Society; BAC, bronchoalveolar carcinoma.
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if it correlated with patient outcome in an Australian surgical
series of stages I, II, and III lung adenocarcinoma.
PATIENTS AND METHODS
Patients
A retrospective review of a prospectively maintained
surgical database was used to identify patients who had
primary lung cancer resected, with curative intent, from 1996
to 2009. All patients had a histopathologic diagnosis of
adenocarcinoma defined as a malignant epithelial neoplasm
with either glandular differentiation or mucin production and
histopathologic patterns including acinar, papillary, BAC, or
solid with mucin or an admixture of these patterns, according
to the 2004 WHO classification.4 Clinical information was
obtained from detailed prospective clinical databases.
The definition of a never smoker was a person with
lifetime equivalent consumption of fewer than 100 cigarettes.
Patients were excluded if they had neoadjuvant therapy,
metastatic disease found at the time of surgery, or additional
tumor nodules (found at the time of surgery or subsequent
macroscopic and/or histopathologic examination). Where the
resection was sublobar (wedge resection or segmentectomy),
or mediastinal sampling or dissection was not performed,
patients were only included if they underwent a definitive
operation with curative intent, in line with the best clinical
practice at the time of surgery.
Ethics approval was obtained from the Human Research
and Ethics Committee at St. Vincent’s Hospital, Melbourne.
Histologic Assessment
Location, number, and size of tumors were obtained
from pathology reports. Two pathologists, blinded to patient
outcome, independently reviewed all hematoxylin and eosin
(HE)-stained slides. An average of five HE slides of tumor
(range: 1–20) were reviewed per case. In 67 cases, the entire
tumor was submitted for histopathologic examination. All
cases were histologically classified according to the 2004
WHO classification.4 Furthermore, each pathologist recorded
in 5% increments each histologic subtype present and iden-
tified and classified each tumor according to the predominant
histologic subtype,5 in line with the new adenocarcinoma
classification.13 The lowest limit for the predominant histo-
logic subtype was set at 30% and identified and documented
by each pathologist independently and blinded from the other
pathologist’s assessment.
Discrepancies between the two pathologists in assign-
ment of the predominant histologic subtype were later re-
solved by consensus at a double-headed microscope.
The amount of lepidic growth13 and an assessment of
the presence or absence of stromal, lymphovascular space,
and pleural invasion2–4 are the key elements in the diagnosis
of AIS, MIA, and LPA. To aid in the assessment of these
latter features and to estimate the amount of lepidic growth
present, we evaluated Verhoff Van Gieson (VVG) elastic
stains in each case in which a component of lepidic growth
was present. The photomicrographs in the study by Sakurai et
al.23 were helpful in our evaluation of VVG stains as they
demonstrate examples of intact elastic framework in areas of
lepidic growth and disrupted elastic framework in areas of
stromal invasion. We observed two patterns of VVG staining
in areas of lepidic growth:
Pattern 1: Strong continuous black staining representing
intact elastic fibers in thickened alveolar walls often associated
with diminution in size of alveolar spaces (Figure 1A).
Pattern 2: Thin, discrete but overlapping elastic fibers
in alveolar walls only slightly thicker than those in the
adjacent pulmonary parenchyma but thinner than pattern 1. It
is very similar to the staining seen in normal pulmonary
parenchyma (Figure 1B).
In line with previous studies, any areas with free-
floating tumor cells in alveolar spaces5 or complex branching
papillary structures,24 which lacked elastic fibers on VVG
stains, were excluded from the definition of lepidic growth. In
tumors with predominant lepidic growth, VVG stains were
also used to identify areas of nonlepidic growth that appeared
as a solid area on low-power magnification (Figure 1C). On
high-power magnification of the VVG stains, the area of
nonlepidic growth mostly showed red-yellow desmoplastic
tumor stroma with surrounding bundles of black broken
elastic fibers and infiltrating acinar pattern or less commonly
papillary pattern adenocarcinoma, indicative of stromal inva-
sion (Figure 1D). At low-power magnification, we drew a line
around the edges of the area of nonlepidic growth at its
interface with the area of lepidic growth. We then measured
the size of the area of nonlepidic growth in its longest
dimension on the glass slide (Figure 2), as described previ-
ously.14,15 If the tumor comprised 100% lepidic growth, we
classified it as AIS. If the tumor showed predominant lepidic
growth and an area of nonlepidic growth 5 mm, we clas-
sified it as MIA13–15; whereas if the area of nonlepidic growth
measured more than 5 mm, we classified it as LPA, estimat-
ing the amounts of lepidic growth and other histologic sub-
types present in 5% increments.13 However, if a tumor with
predominant lepidic growth showed tumor necrosis or inva-
sion of lymphovascular spaces or visceral pleura, we classi-
fied it as LPA, in line with the new classification.
Acinar adenocarcinoma was diagnosed in tumors with
infiltrating glands with or without luminal or cytoplasmic
mucin (Figure 3A). In contrast to areas of lepidic growth
where the elastic framework of the lung is intact, acinar
adenocarcinoma has stromal invasion, as evidenced by dis-
ruption of the elastic framework with bundles of broken
elastic fibers seen on VVG stains accompanied by desmo-
plastic tumor stroma10 and haphazardly arranged, irregularly
shaped glands. Adenocarcinomas with cribriform structures
comprising solid nests of tumor cells with well-defined
“punched-out” glandular lumina, with or without mucin, were
included for analysis with acinar-predominant adenocarci-
noma, in line with the definition of acinar/tubular adenocar-
cinoma by Noguchi et al.3
Papillary adenocarcinoma was diagnosed in tumors
with complex branching papillae with fibrovascular cores
lined by tumor cells.24 We found VVG stains useful in the
distinction between lepidic growth and papillary adenocarci-
noma. As shown in Figure 3B, the absence of VVG staining
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in papillae of papillary adenocarcinoma indicated stromal
invasion.3,24
Micropapillary pattern adenocarcinoma was diagnosed
in tumors with small papillary tufts of tumor cells without
fibrovascular cores either lying apparently free in alveolar
spaces or surrounded by thin fibrous septa (Figure 3C), often
at a tumor’s edge, or as a nodular configuration surrounded
by broader bands of desmoplastic stroma, seen more centrally
within a tumor.10–12
In tumors with any component of solid carcinoma,
Alcian blue-Periodic Acid Schiff stains with diastase dif-
ferentiation were performed to evaluate the presence or
absence of mucin. Solid adenocarcinoma with mucin pro-
duction was diagnosed if intracellular mucin was present
in at least five tumor cells in two high-power fields with
Alcian blue-Periodic Acid Schiff stains with diastase dif-
ferentiation (Figure 3D).4,13
Invasive mucinous adenocarcinoma, formerly muci-
nous BAC, was diagnosed in tumors with lepidic growth of
columnar or goblet cells with abundant intracellular mucin
admixed with invasive adenocarcinoma patterns including
acinar, papillary, micropapillary, and solid growth accompa-
nied by areas of stromal invasion (Figure 3E).13
In the new classification, tumors with cystic changes
seen macroscopically and/or microscopically, formerly called
mucinous cystadenocarcinoma, are now included with colloid
adenocarcinoma.13 Colloid adenocarcinoma was diagnosed in
tumors with abundant pools of extracellular mucin that ex-
pand and variably destroy alveolar walls, some lined by or
containing apparently free-floating clusters of tumor cells
with columnar cytoplasm with intracellular mucin or goblet
cell morphology.13
Clear cell25 and signet ring26 cytologic changes were
classified according to the subtype in which such cytologic
changes occurred, in line with the new classification.13 Ma-
lignant giant cells, if 10% of the total tumor, were included
as part of the solid subtype. A malignant giant-cell compo-
nent more than 10% was classified as pleomorphic carci-
noma4 and excluded from further analysis.
FIGURE 1. Morphology of adeno-
carcinoma in situ and minimally in-
vasive adenocarcinoma with VVG
stains. A, Pattern 1 with VVG stains
comprises continuous black staining
in thickened alveolar walls repre-
senting intact elastic fibers often
associated with diminution in size of
alveolar spaces, indicative of the
absence of stromal invasion (VVG,
100). B, Pattern 2 with VVG stains
comprises thin, discrete but overlap-
ping elastic fibers in alveolar walls
only slightly thicker than those in
the adjacent lung but thinner than
pattern 1 (VVG, 200). C, A solid
area of nonlepidic growth in a tu-
mor that otherwise shows predomi-
nant lepidic growth as seen with
VVG stains (VVG, 20). D, With
VVG stains the solid area shows red-
yellow desmoplastic tumor stroma,
bundles of black broken elastic fi-
bers, and infiltrating acinar pattern
adenocarcinoma, indicative of stro-
mal invasion (VVG, 400). VVG,
Verhoff Van Gieson.
FIGURE 2. At low-power magnification, we drew a line
around the edges of the area of nonlepidic growth at its inter-
face with the area of lepidic growth and measured the size of
the area of nonlepidic growth in its longest dimension on the
glass slide (VVG, 20). VVG, Verhoff Van Gieson.
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Visceral pleural invasion was assessed in all cases, using
guidelines of the 7th edition of the TNM classification for lung
cancer.27,28 In cases with indeterminate visceral pleural invasion,
VVG stains were used. All cases were examined for lympho-
vascular space, perineural, and intraneural invasion. All hilar and
mediastinal lymph nodes included with each case were exam-
ined to assess nodal disease status.
Tumor grade of differentiation was assessed according
to the 2004 WHO classification4 with allocation of tumors
into well, moderate, or poorly differentiated categories.
Statistical Analysis
The relationship between overall survival and each
separate histopathologic subtype/variant according to the new
classification was assessed using the Kaplan-Meier method
for 5-year survival rates. Univariate and multivariate analyses
using Cox regression were undertaken to assess the histo-
pathologic subtype/variant as an independent prognostic fac-
tor for survival. The following variables were included in the
univariate analysis: Pathological 7th edition TNM stage, sex,
age, nodal disease, pleural invasion, lymphatic invasion,
vascular invasion, and tumor diameter. Multivariate analysis
was used for variables that were found to be significant in the
univariate analysis.
RESULTS
Patient Characteristics
Adenocarcinoma was diagnosed in 264 resected spec-
imens according to the final pathology report. Two hundred
ten patients met the inclusion criteria. Of these, 54% (n 
113) were men and 46% (n  97) were women. The median
age was 67 years (Table 2). Current smokers constituted 20%
of patients, with 61% of patients being past smokers and 19%
never smokers. Lobectomy was performed in 79% of patients
(n  165), wedge resection in 7% (n  16), bilobectomy in
5% (n  11), segmentectomy in 5% (n  10), and pneumo-
nectomy in 4% (n  8).
Locations of tumors are listed in Table 2. Mediastinal
lymph node dissection was performed in 86% of patients
(n  181); hilar or mediastinal lymph node sampling was
performed in 7% of patients (n  14), and no lymph node
dissection in 7% of patients (n  15). Of the patients without
lymph node sampling during the procedure, 14 had preoper-
ative nodal assessment with invasive (mediastinoscopy/me-
diastinotomy/endobronchial ultrasound) or noninvasive (pos-
itron emission scanning) procedures.
Tumor size ranged from 9 to 140 mm with a median
size of 29 mm.
FIGURE 3. Morphology of adenocarcinoma
subtypes and variants. A, Acinar pattern adeno-
carcinoma comprises jagged haphazardly ar-
ranged glands with or without luminal or cyto-
plasmic mucin infiltrating desmoplastic tumor
stroma (HE, 200). B, With VVG stains the pa-
pillae of papillary pattern adenocarcinoma
show no black elastic fibers in their fibrovascu-
lar cores indicative of stromal invasion (VVG,
200). C, Micropapillary pattern adenocarci-
noma comprises small papillary tufts of tumor
cells without fibrovascular cores either lying
apparently free in alveolar spaces or sur-
rounded by thin fibrous septa (HE, 200). D,
Solid with mucin pattern adenocarcinoma
comprises nests of tumor cells that show intra-
cytoplasmic mucin with Alcian blue-Periodic
Acid Schiff stains with diastase differentiation
(AB-PASD, 200). E, Invasive mucinous adeno-
carcinoma shows peripheral foci of lepidic
growth of columnar or goblet cells with abun-
dant intracellular mucin admixed with invasive
adenocarcinoma patterns (HE, 100). VVG, Ver-
hoff Van Gieson; HE, hematoxylin and eosin.
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Table 3 shows the pathologic TNM stage of the 210
patients. All patients with AIS, MIA, and LPA were stage I.
There was an even distribution of stages I to IIIA with solid
predominant and micropapillary-predominant adenocarcino-
mas. Patients with acinar-predominant and papillary-predom-
inant adenocarcinomas had a greater proportion of patients in
stage I, but a substantial proportion in stages II to IIIA.
Histologic Features
Histologic assessment according to the 2004 WHO
classification found 93% (n  196) of cases were mixed
subtype adenocarcinoma. Pure acinar adenocarcinoma
(100%) was seen in 2.5% (n  5) of cases; 2% (n  4) had
almost 100% solid with mucin adenocarcinoma; 1% (n  2)
had 100% colloid adenocarcinoma, and 1% (n  2) had
almost 100% papillary adenocarcinoma. There was one case
(0.5%) with 100% nonmucinous lepidic growth. Tumor grad-
ing showed 18% (n 38) well-differentiated, 51% (n 107)
moderately differentiated, and 31% (n  65) poorly differ-
entiated tumors.
Histologic assessment according to the new adenocar-
cinoma classification showed 40% (n  84) of cases were
acinar-predominant, which was the most common histologic
subtype, followed by 23% (n  49) solid with mucin-
predominant, 12% (n  26) papillary-predominant, 7% (n 
14) micropapillary-predominant, and 5% (n  10) LPA. There
were 3% (n 7) cases of MIA and one case of AIS (1%). Of the
variant adenocarcinomas, 5% (n 10) were invasive mucinous
adenocarcinoma and 4% (n  9) were colloid-predominant
adenocarcinoma. No cases of mucinous AIS or MIA or fetal or
enteric adenocarcinoma were identified.
The single case of AIS measured 10 mm and was
entirely submitted for histopathologic examination. All cases
of MIA measured less than 30 mm with a range of 9 to 25
mm, a median size of 15 mm, and 6 of 7 cases were entirely
submitted for histopathologic examination. The largest MIA
was 25 mm in diameter and had only two blocks submitted,
both of which showed predominant lepidic growth with an
FIGURE 4. The largest minimally invasive adenocarcinoma
showed predominant lepidic growth with an intact elastic
framework seen on VVG stains and a 4 mm area of nonle-
pidic growth comprising infiltrating acinar adenocarcinoma,
desmoplastic tumor stroma, and irregular bundles of elastic
fibers (VVG, 40). VVG, Verhoff Van Gieson.
TABLE 3. Pathologic Stage of the 210 Patients According
to the 7th Revision TNM Classification and the Predominant
Histologic Subtype/Variant
Predominant
Subtype
Stage
IA
Stage
IB
Stage
IIA
Stage
IIB
Stage
III Total
AIS 1 0 0 0 0 1
MIA 7 0 0 0 0 7
Lepidic 5 5 0 0 0 10
Acinar 27 25 15 6 11 84
Papillary 9 9 5 2 1 26
Solid 12 14 10 5 8 49
Micropapillary 4 3 0 1 6 14
Mucinous 1 4 1 4 0 10
Colloid 1 3 1 0 4 9
Total 67 64 31 18 30 210
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma.
TABLE 2. Clinical Details of the Included 210 Patients with
Stages I, II, and III Lung Adenocarcinoma
Total Male Female
Sex (%) 210 113 (54) 97 (46)
Age (ys)
Range 30–91 30–91 29–84
Median 67 67 66
Smoking status (%)
Current 42 (20) 19 (9) 23 (11)
Ever 128 (61) 83 (39) 45 (22)
Never 40 (19) 11 (5) 29 (14)
Procedure (%)
Wedge 16 (7) 10 (4) 6 (3)
Segmentectomy 10 (5) 4 (2) 6 (3)
Lobectomy 165 (79) 85 (41) 80 (38)
Bilobectomy 11 (5) 6 (3) 5 (2)
Pneumonectomy 8 (4) 8 (4) 0 (0)
Lymph nodes (%)
Mediastinal 181 (86) 97 (46) 84 (40)
Hilar 14 (7) 8 (4) 6 (3)
No lymph nodes 15 (7) 9 (4) 6 (3)
Tumour size (mm)
Range 9–140 9–140 10–90
Median 29 29 28
Tumour location (%)
RUL 90 (43) 56 (27) 34 (16)
RML 9 (4) 4 (1) 5 (3)
RLL 35 (17) 20 (10) 15 (7)
LUL 48 (23) 20 (9) 28 (14)
Lingula 2 (1) 1 (0.5) 1 (0.5)
LLL 26 (12) 12 (5) 14 (7)
RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left
upper lobe; LLL, left lower lobe.
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intact elastic framework seen on VVG stains, with one slide
showing a 4 mm area of nonlepidic growth comprising
infiltrating acinar adenocarcinoma, desmoplastic tumor
stroma, and irregular bundles of elastic fibers (Figure 4). This
patient, operated on in 2003, is alive with no evidence of
disease after more than 7 years of follow-up. Lobectomy with
mediastinal lymph node dissection was performed in the case
of AIS and 6 of 7 cases of MIA. The seventh case of MIA had
a wedge resection and a negative postoperative positron
emission tomography scan and is alive with no evidence of
disease after more than 8 years of follow-up.
The 10 cases of LPA ranged in size from 9 to 45 mm
with a median size of 23.5 mm, and 7 of 10 tumors were
entirely submitted for histopathologic examination. The
amount of lepidic growth ranged from 40 to 60% (median,
52.5%). The three cases of LPA not entirely submitted
measured 19 mm with two blocks submitted, 40 mm with
three blocks submitted, and 45 mm with five blocks submit-
ted. These three surgeries were performed in 2003 (19 and 40
mm tumor cases) and 2005 (45 mm tumor case), before
implementation of our policy of submitting the entire tumor.
None of the cases of AIS, MIA, or LPA had lymph
node metastases or lymphovascular space invasion (Table 4).
No case of AIS or MIA had visceral pleural invasion; how-
ever, 2 of 10 cases of LPA had visceral pleural invasion seen
in an 18-mm tumor and a 22-mm tumor, both of which were
entirely submitted for histopathologic examination. In addi-
tion, the 18-mm tumor showed a small focus of tumor cells
on the visceral pleural surface (see Survival Correlation).
Twenty-two of 84 cases of acinar-predominant, 14 of
49 cases of solid with mucin-predominant, 9 of 26 cases of
papillary-predominant, and 3 of 14 cases of micropapillary-
predominant adenocarcinoma were entirely submitted for
histopathologic examination.
Micropapillary-predominant adenocarcinoma showed
the highest incidence of N2 metastases and invasion of
lymphovascular spaces and visceral pleura in comparison
with acinar-predominant, papillary-predominant, and solid
with mucin-predominant adenocarcinomas (Table 4).
Three of 10 cases of invasive mucinous adenocarci-
noma and 2 of 9 cases of colloid-predominant adenocarci-
noma were entirely submitted for histopathologic examina-
tion. All 10 cases of invasive mucinous adenocarcinoma had
more than 5 mm invasion comprising different architectural
patterns. However, each case showed a variable proportion of
lepidic growth of tumor cells with columnar or goblet cell
appearance with abundant intracellular mucin ranging from
20 to 60% (median, 30%).13 Two of the nine cases of colloid
adenocarcinoma (measuring 35 and 50 mm, neither of which
were entirely submitted for histopathologic examination)
showed 100% of this pattern, whereas the other seven cases
showed predominance of the colloid adenocarcinoma pattern,
ranging from 40 to 70% (median, 50%). Twenty-two percent
of colloid adenocarcinoma cases showed N1 and N2 metas-
tases and vascular space invasion, and 56% showed visceral
pleural invasion, whereas 20% of invasive mucinous adeno-
carcinoma cases showed visceral pleural invasion only.
Survival Correlation
Postoperative 30-day mortality was 2.4% (5/210), and
two other patients died of disease within 6 months. The
median follow-up was 49 months (range: 3–176 months).
Histologic subtyping predicted survival when controlling for
known prognostic variables in univariate analysis (p 
0.008). The prognostic value of histologic subtyping persisted
in multivariate analysis (p 0.045). To increase the power of
the analysis, adenocarcinoma subtypes with similar 5-year
survival rates were then combined, to give four groups for
further analysis (Figure 5). Group 1 consisted of AIS, MIA,
and LPA; group 2 consisted of acinar- and papillary-predom-
inant adenocarcinoma; group 3 consisted of micropapillary-
and solid with mucin-predominant adenocarcinoma; and
group 4 consisted of invasive musinous and colloid adeno-
carcinoma. These groups predicted survival in both univariate
(p  0.001) and multivariate analysis (p  0.001).
The single case of AIS and seven cases of MIA had
100% 5-year survival. The 10 cases of LPA had 86% 5-year
survival with only one death. All cases of AIS, MIA, and
LPA were stage I and grouped together had a 93% 5-year
survival (Figure 5; Table 5). Two cases of LPA showed
visceral pleural invasion; of these, one patient with an 18-mm
tumor completely submitted for histopathologic examination
TABLE 4. Invasive Features of 210 Resected Tumors Classified According to the IASLC/ATS/ERS
International Multidisciplinary Lung Adenocarcinoma Classification
Major Subtype n (%)
Lymph
Node N1
Lymph
Node N2
Lymphatic
Invasion
Vascular
Invasion
Visceral
Pleural
Invasion
AIS 1 (1) 0 0 0 0 0
MIA 7 (3) 0 0 0 0 0
Lepidic 10 (5) 0 0 0 0 2 (20)
Acinar 84 (40) 14 (17) 9 (11) 27 (32) 37 (44) 30 (36)
Papillary 26 (12) 5 (19) 1 (4) 10 (38) 9 (35) 9 (35)
Micropapillary 14 (7) 0 6 (43) 12 (86) 13 (93) 8 (57)
Solid with mucin 49 (23) 10 (21) 7 (14) 22 (44) 31 (63) 17 (35)
Mucinous 10 (5) 0 0 0 0 2 (20)
Colloid 9 (4) 2 (22) 2 (22) 2 (22) 1 (11) 5 (56)
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma.
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had 60% lepidic growth and 40% acinar pattern adenocarci-
noma, without luminal mucin, and had visceral pleural inva-
sion with tumor cells on the visceral pleural surface. There
was no lymphovascular space invasion, and mediastinal
lymph node assessment was negative. This patient developed
mediastinal disease 3 years after resection. The mediastinos-
copy specimen at the time of recurrence showed acinar
pattern adenocarcinoma with luminal mucin as opposed to the
original LPA. This suggests that the mediastinal metastasis
may have arisen from a second new primary based on the
morphologic differences between the two tumors.29
The 84 cases of acinar-predominant adenocarcinoma
had 68% 5-year survival, and the 26 cases of papillary-
predominant adenocarcinoma had 71% 5-year survival. The
14 cases of micropapillary-predominant had 38% 5-year
survival, and 49 cases of solid with mucin-predominant
adenocarcinoma had 39% 5-year survival (Figure 5; Table 5).
Both the variants, consisting of 10 cases of invasive muci-
nous adenocarcinoma and the 9 cases of colloid adenocarci-
noma, had 51% 5-year survival (Figure 6; Table 5).
DISCUSSION
In this study, we have shown a significant correlation
between 5-year survival and histologic subtype of adenocar-
cinoma based on the diagnostic criteria of the new IASLC/
ATS/ERS international multidisciplinary lung adenocarci-
noma classification in a cohort of 210 resected stages I, II,
and III lung adenocarcinomas.
Furthermore, we have demonstrated that in our cohort,
classification of adenocarcinoma according to the new clas-
sification is the strongest predictor of patient survival, inde-
pendent of the gold standard of the 7th edition of TNM
staging for lung cancer. In contrast, we found that classifica-
tion of the same cohort according to the 2004 WHO classi-
fication did not provide useful prognostic information, as
93% were classified as mixed subtype adenocarcinomas. This
limitation of the 2004 WHO classification has recently been
emphasized by several groups,5–7 some of which have at-
tempted to implement a more meaningful classification sys-
tem that provides prognostic information and has relevance to
clinical behavior.5,7,30
Histopathologic classification systems have tradition-
ally been the domain of pathologists. However, there is a
trend for development of classifications systems by multidis-
ciplinary panels of experts, a recent example being the 2008
WHO Classification of Hemopoietic and Lymphoprolifera-
tive Tumors.31 In addition, some entities in this latter classi-
fication are now defined by the combination of a morphologic
phenotype tightly correlated to a molecular profile. This
enables clinicians to recommend individualized therapy,
when available, to such patients. The shifting paradigm to-
ward individualized therapy has been evolving in lung cancer
management over the past decade. An updated, multidisci-
plinary approach to the classification of lung adenocarcinoma
will encourage and enable continued research into the corre-
FIGURE 5. Correlation of 5-year survival with the predomi-
nant histologic subtype revealed significant differences in
survival (p  0.0001) between 18 cases of AIS, MIA, and
lepidic-predominant tumors (93% 5-year survival), 26 cases
of papillary-predominant (71% 5-year survival), 84 cases of
acinar-predominant (68% 5-year survival), 49 cases of solid
with mucin-predominant (39% 5-year survival), and 14 cases
of micropapillary-predominant (38% 5-year survival) adeno-
carcinoma.
FIGURE 6. The small number of adenocarcinoma variants,
invasive mucinous adenocarcinoma, and colloid adenocarci-
noma, each had an intermediate to poor prognosis of 51%
5-year survival.
TABLE 5. Correlation of the Predominant Histologic
Subtype or Variant with 5-Year Survival in 210 Patients
Predominant Histologic Subtype/Variant
No. of
Patients
5-Year
Survival (%)
Adenocarcinoma in situ 1 100
Minimally invasive adenocarcinoma 7 100
Lepidic predominant 10 86
Papillary predominant 26 71
Acinar predominant 84 68
Invasive mucinous adenocarcinoma 10 51
Colloid predominant 9 51
Solid with mucin predominant 49 39
Micropapillary predominant 14 38
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lation of morphologic phenotype with the underlying molec-
ular correlate.
The patient cohort presented in this study differs from
other retrospective clinicopathologic studies22 as it compre-
hensively subtypes adenocarcinoma in patients with not only
stage I but also stages II and III lung adenocarcinoma. We
have included patients with stages II and III lung adenocar-
cinoma in our data set as this represents real-world practice.
It may be argued that solid with mucin and micropapillary-
predominant adenocarcinomas had poorer prognosis in our
cohort purely because of higher N stage, pleural invasion, and
so on. However, the fact that two independent pathologists,
blinded to outcome and other prognostic factors, were highly
concordant with their classification of the primary tumor
suggests this is a robust predictor of aggressive tumor behav-
ior. In addition, it may be that these tumors largely present at
a later stage.
This work must be further prospectively validated,
ideally in population-based studies. Although the ability to
accurately prognosticate is goal enough, there are the addi-
tional benefits of facilitating a more rational provision of
follow-up resources, recruitment into clinical trials of adju-
vant therapies, and better patient matching in trials of new
and existing therapies. Confirmation of these findings could
also provide an opportunity to refine future genomic and gene
expression profiling studies to concentrate on specific sub-
types, thereby reducing noisy signals and increasing the
power to detect putative oncogenes.
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